Panacea Biotec

OverviewSuggest Edit

Panacea Biotec is a company involved in research, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and natural products. Its product portfolio includes prescription products in therapeutic areas such as pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, as well as gastro-intestinal care products and vaccines.
TypePublic
Founded1994
Websitepanaceabiotec.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Mar 2019)2,600
Revenue (FY, 2021)₹6.2 B(+15%)
Share Price (Jun 2022)₹127.8(-6%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Panacea Biotec Financials and Metrics

Panacea Biotec Revenue

Panacea Biotec's revenue was reported to be ₹6.18 b in FY, 2021
INR

Revenue (Q3, 2022)

1.6b

Gross profit (Q3, 2022)

1.1b

Net income (Q3, 2022)

(492.0m)

EBITDA (Q3, 2022)

135.2m

EBIT (Q3, 2022)

29.7m

Market capitalization (17-Jun-2022)

7.8b

Closing stock price (17-Jun-2022)

127.8

EV

7.8b
Panacea Biotec's current market capitalization is ₹7.8 b.
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

5.7b4.5b5.4b6.2b

Cost of goods sold

(2.1b)(2.0b)(1.7b)(2.3b)

Gross profit

3.9b2.6b3.7b4.0b

R&D expense

(618.1m)(247.7m)
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Revenue

951.1m1.2b1.1b1.3b1.3b1.7b1.3b1.8b1.4b1.3b2.3b1.6b

Cost of goods sold

(314.1m)(408.5m)(317.6m)(280.7m)(368.9m)(522.8m)(394.4m)(638.0m)(425.1m)(426.3m)(1.0b)(465.9m)

Gross profit

670.3m810.3m862.1m1.0b917.4m1.2b945.1m1.2b1.0b930.5m1.3b1.1b
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021

Cash

232.4m234.8m897.5m1.4b

Accounts Receivable

1.4b887.3m685.2m846.8m

Prepaid Expenses

110.5m116.0m141.5m118.1m

Inventories

3.3b814.3m1.5b1.7b
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Cash

162.2m1.2b1.0b1.4b

Accounts Receivable

1.2b858.3m942.1m1.2b

Inventories

1.4b1.1b1.5b2.1b
Annual
INRFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(661.4m)462.3m(1.7b)(1.4b)

Depreciation and Amortization

585.3m550.3m441.4m460.7m

Inventories

(188.3m)847.6m(662.6m)(264.4m)

Accounts Payable

312.7m75.1m(496.9m)235.1m
Quarterly
INRQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Net Income

(983.3m)(523.6m)(1.1b)

Depreciation and Amortization

229.0m231.9m219.7m

Inventories

(270.9m)(49.5m)(332.0m)

Accounts Payable

(688.7m)182.9m1.3b
Show all financial metrics

Panacea Biotec Revenue Breakdown

Embed Graph

Panacea Biotec revenue breakdown by business segment: 63.5% from FORMULATIONS and 36.5% from VACCINES

Panacea Biotec Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Panacea Biotec Online and Social Media Presence

Embed Graph

Panacea Biotec News and Updates

Panacea Biotec Shares Gain On Sale Of Domestic Formulations Brands To Mankind

Panacea Biotec Pharma has agreed to sell its formulations brands in India and Nepal to Mankind.

Stocks To Watch: Reliance Industries, Tata Power, Wipro, Rossari Biotech, Panacea Biotec

Here are the stocks to watch in trade today...

RDIF, Panacea Biotec launch production of Sputnik V vaccine in India

The first batch of the COVID-19 vaccine produced at Panacea Biotec's facilities at Baddi in Himachal Pradesh will be shipped to Russia for quality control.

Panacea Biotec e Refana anunciam colaboração histórica para vacina contra a COVID-19

NOVA DÉLHI, 11 de junho de 2020 /PRNewswire/ -- A Panacea Biotec está promovendo sua resposta para lidar com os desafios sem precedentes da COVID-19, ao colaborar com a Refana Inc. USA para disponibilizar uma vacina contra a COVID-19, amplamente acessível em todo o mundo, de uma maneira...

Panacea Biotec y Refana anuncian colaboración histórica para la vacuna contra el COVID-19

NUEVA DELHI, 11 de junio de 2020 /PRNewswire/ -- Panacea Biotec avanza en su respuesta para abordar los desafíos sin precedentes del COVID-19 al forjar una colaboración con Refana Inc. USA para que la vacuna contra el COVID-19 esté disponible en todo el mundo de manera equitativa a través...

Panacea Biotec und Refana kündigen richtungsweisende Zusammenarbeit für COVID-19-Impfstoff an

- Die Zusammenarbeit wird die globale Entwicklung, Herstellung und Verteilung des COVID-19-Impfstoffkandidaten ermöglichen NEW DELHI, 11. Juni 2020 /PRNewswire/ -- Panacea Biotec treibt seine Antwort auf die beispiellosen Herausforderungen von COVID-19 voran, indem es mit Refana Inc. USA...
Show more

Panacea Biotec Frequently Asked Questions

  • When was Panacea Biotec founded?

    Panacea Biotec was founded in 1994.

  • How many employees does Panacea Biotec have?

    Panacea Biotec has 2,600 employees.

  • What is Panacea Biotec revenue?

    Latest Panacea Biotec annual revenue is ₹6.2 b.

  • What is Panacea Biotec revenue per employee?

    Latest Panacea Biotec revenue per employee is ₹2.4 m.

  • Who are Panacea Biotec competitors?

    Competitors of Panacea Biotec include Centrient Pharmaceuticals, Procos and Medley Pharmaceuticals.